跟随财团用国际视野看待创新药
In terms of market space, from the perspective of the scale of the innovative drug market, the global innovative drug market in 2023 is about 830 billion US dollars, of which the US market accounts for 55%, while the Chinese innovative drug market only accounts for 3% of the global market. From the perspective of drug sales structure in China and the United States, in 2023, the sales of innovative drugs in the United States accounted for 79% of all drug sales, while domestic sales of innovative drugs accounted for only 11% of national drug sales. Compared with the domestic market, developed countries overseas have a broader potential for innovative drug markets. In terms of drug pricing, in 2023, the per capita health expenditure in China was 5439.97 yuan (equivalent to 754.30 US dollars), while the per capita health expenditure in the United States was 12914 US dollars that year, which is 17.12 times that of China. From the perspective of the medical insurance system structure in China and the United States, China's medical insurance system is mainly based on social medical insurance, while the medical insurance system in the United States is mainly based on commercial medical insurance. From the perspective of the positioning of China's basic medical insurance, it is necessary to comprehensively consider the medication security needs of 1.35 billion insured individuals and the actual payment capacity of the medical insurance fund. In terms of commercial insurance, although China's commercial health insurance has steadily developed in recent years, the absolute value and proportion of commercial health insurance are still relatively low. Compared with developed countries such as the United States, the payment support for innovative drugs is relatively limited. In 2023, the amount of compensation expenses for commercial health insurance in China accounted for 12.74% of China's medical insurance expenses, while commercial medical insurance in the United States accounted for 40.14% of its overall health insurance expenses. Taking into account various factors such as the level of economic development and the structure of the medical security system, developed countries may have a more relaxed pricing space for innovative drugs, which can bring higher returns to innovative drug research and development. Chinese pharmaceutical companies will gradually approach international pharmaceutical companies!